Inocucor Technologies Closes $38.8M Series B Financing12 months ago -
Inocucor Technologies Inc., an innovator and producer of biological crop inputs, completed a $38.8 million CAD first close of its Series B financing round. The lead investor in the first close is TPG Alternative and Renewable Technologies (TPG ART), a growth-equity and late-stage venture capital vehicle of global alternative asset firm TPG.
Inocucor uses a patented fermentation process to combine multi-strains of bacteria and yeasts into soil and plant optimizers that are safe for people and the environment. These products naturally improve crop yields, shorten growing periods and create healthier, more resilient soils for farmers and greenhouse growers.
“This investment speaks to TPG ART’s strategy of partnering with unique companies that are deploying innovative business models and technologies to reduce environmental impact and promote resource efficiency,” says Geoff Duyk, partner at TPG ART. ”We’re excited to work with Inocucor’s management team and other investors to help grow the company.”
In connection with the investment, Duyk joined Inocucor’s board of directors.
Other participants in this first Series B round are Cycle Capital Management, the Montreal-based clean tech venture capital firm that made its first investment in Inocucor in late 2013; Desjardins Innovatech, another original investor and the venture capital group of Desjardins, one of Canada’s cooperative financial groups with more than $200 billion in assets; and Closed Loop Capital, an early-stage venture capital fund investing in agriculture technologies and food system innovations.
Funds will support opening a U.S. headquarters and commercialization office, significantly increasing manufacturing capacity at Inocucor’s Montreal pilot production and R&D facility, and adding managerial and scientific expertise to Inocucor’s staff.
“The specialty ag biologicals sector is one of agriculture’s bright spots, answering the need for sustainable agriculture inputs that help growers improve yields and invigorate soil,” says Donald Marvin, Inocucor president and CEO . “Our corporate strategy includes staking our claim as a market leader in this emerging segment by growing organically with our own proprietary microbial consortia technology while also pursuing strategic acquisitions and product development partnerships in North America, Latin America and Western Europe.”
Andrée-Lise Méthot, founder and managing partner of Cycle Capital Management, says her firm sees a very bright future for Inocucor. “Inocucor has come a long way since our first investment. It has products on the market, being used by growers who are experiencing positive results. The promise we saw in those early days is coming to fruition,” she adds.
Inocucor’s flagship product, Garden Solution, soon to be rebranded in the U.S. as Synergro, is a live-cell formulation for high-value produce, such as strawberries, tomatoes, lettuce and broccoli. Synergro Free is a cell-free bio-fertilizer additive to existing plant nutrients for commodity row crops, such as soybean, corn and wheat. Inocucor’s new-product development pipeline includes bio-control formulations that combat economically devastating diseases in crops such as strawberries, tomatoes and potatoes.
Both products are among the first microbial products of their kind to be registered in Canada. In the U.S., Garden Solution (Synergro) is OMRI Listed nationally and OIM-registered in California for organic production. It is registered for use in 22 U.S. states. Synergro Free is registered in 16 U.S. states.[rate_this_page]